Log in

Relevant bibliographies by topics / Cardioncologia / Journal articles

To see the other types of publications on this topic, follow the link: Cardioncologia.

Journal articles on the topic 'Cardioncologia'

Author: Grafiati

Published: 11 March 2023

Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Cardioncologia.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Cardinale, Daniela Maria. "Ruolo dei biomarcatori cardiaci in cardioncologia nell’identificazione precoce della cardiotossicità." Cardiologia Ambulatoriale 2, no. 2 (2024): 167–82. http://dx.doi.org/10.17473/1971-6818-2024-2-7.

Full text

Abstract:

La cardiotossicità è un importante effetto collaterale delle terapie antitumorali che influisce sulla qualità della vita e sulla sopravvivenza complessiva dei pazienti oncologici. La diagnosi precoce è cruciale per l’applicazione di strategie terapeutiche preventive e di supporto. La misurazione dei biomarcatori cardiaci specifici può diventare un metodo di routine utile per identificare i pazienti più inclini a sviluppare cardiotossicità e nei quali una strategia farmacologica preventiva e un monitoraggio cardiaco più stretto sono fondamentali. Sia le troponine che i peptidi natriuretici hann

APA, Harvard, Vancouver, ISO, and other styles

2

Todaro, Maria Chiara, Lilia Oreto, Rubina Qamar, Timothy E. Paterick, Scipione Carerj, and Bijoy K. Khandheria. "Cardioncology: State of the heart." International Journal of Cardiology 168, no. 2 (2013): 680–87. http://dx.doi.org/10.1016/j.ijcard.2013.03.133.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Penna, Claudia. "Redox and Nitrosative Signaling and Stress." Antioxidants 9, no. 12 (2020): 1237. http://dx.doi.org/10.3390/antiox9121237.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Chatterjee, Shambhabi, Shashi Kumar Gupta, Christian Bär, and Thomas Thum. "Noncoding RNAs: potential regulators in cardioncology." American Journal of Physiology-Heart and Circulatory Physiology 316, no. 1 (2019): H160—H168. http://dx.doi.org/10.1152/ajpheart.00418.2018.

Full text

Abstract:

Cancer is the leading cause of morbidity and mortality in the United States and globally. Owing to improved early diagnosis and advances in oncological therapeutic options, the number of cancer survivors has steadily increased. Such efficient cancer therapies have also lead to alarming increase in cardiovascular complications in a significant proportion of cancer survivors, due to adverse cardiovascular effects such as cardiotoxicity, cardiac atrophy, and myocarditis. This has emerged as a notable concern in healthcare and given rise to the new field of cardioncology, which aims at understandi

APA, Harvard, Vancouver, ISO, and other styles

5

Cardinale, Daniela, Vincenzo Caruso, and Carlo M. Cipolla. "The breast cancer patient in the cardioncology unit." Journal of Thoracic Disease 10, S35 (2018): S4306—S4322. http://dx.doi.org/10.21037/jtd.2018.10.06.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Lestuzzi, C. "Cardioncology, oncocardiology. Are we barking up the wrong tree?" International Journal of Cardiology 167, no. 2 (2013): 307–9. http://dx.doi.org/10.1016/j.ijcard.2013.04.148.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Printz, Carrie. "International Cardioncology Society tackles heart problems in cancer patients." Cancer 117, no. 9 (2011): 1785–87. http://dx.doi.org/10.1002/cncr.26155.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Throndson, K., D. Grantham, and B. Laurila. "Nursing Collaboration to Improve Management of CardiOncology In-Patient Population." Canadian Journal of Cardiology 32, no. 10 (2016): S330. http://dx.doi.org/10.1016/j.cjca.2016.07.582.

Full text

APA, Harvard, Vancouver, ISO, and other styles

9

Printz, Carrie. "Cardioncology pioneer sees promise in new drugs, case management approaches." Cancer 117, no. 9 (2011): 1787. http://dx.doi.org/10.1002/cncr.26157.

Full text

APA, Harvard, Vancouver, ISO, and other styles

10

Chazova, I. E., E. V. Oschepkova, M. Yu Kirillova, and G. Ch Sharipova. "Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy." Systemic Hypertension 12, no. 2 (2015): 6–7. http://dx.doi.org/10.26442/sg29054.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Tarantini, L., A. Camerini, M. L. Canale, et al. "THROUGH AND BEYOND COVID-19 PANDEMIC: A NEW SCENARIO FOR CARDIONCOLOGY." Annals of Research in Oncology 01, no. 04 (2021): 303. http://dx.doi.org/10.48286/aro.2021.27.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Sonaglioni, Andrea, Adriana Albini, Emanuela Fossile, et al. "Speckle-Tracking Echocardiography for Cardioncological Evaluation in Bevacizumab-Treated Colorectal Cancer Patients." Cardiovascular Toxicology 20, no. 6 (2020): 581–92. http://dx.doi.org/10.1007/s12012-020-09583-5.

Full text

APA, Harvard, Vancouver, ISO, and other styles

13

Zamaldinov, N. D., S. A. Malamagomedova, and A. O. Kelin. "Cardioncology of children’s patients: an interdisciplinary approach to treatment and supportive therapy." CARDIOMETRY, no. 23 (August 20, 2022): 54–57. http://dx.doi.org/10.18137/cardiometry.2022.23.5457.

Full text

Abstract:

The paper investigates the features of an interdisciplinary approach in the field of treatment and supportive therapy of pediatric patients with oncological diagnoses having concomitant problems in the field of cardiology. The authors note that the formation of an interdisciplinary approach in the field of prevention and treatment of cardiopathologies in children with cancer will eliminate gaps in the knowledge of specialists and improve the results of treatment of children with cancer. Early detection of cardiovascular diseases and preventive initiation of drug treatment improves the quality

APA, Harvard, Vancouver, ISO, and other styles

14

Zambelli, Alberto, Matteo Della Porta, and Vittorio Rosti. "From cancer patients to cancer survivors: The issue of Cardioncology – A biological perspective." European Journal of Cancer 46, no. 4 (2010): 697–702. http://dx.doi.org/10.1016/j.ejca.2009.12.011.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Canale, Maria Laura. "L’individuazione e il trattamento precoce dello scompenso cardiaco da cardiotossicità." Cardiologia Ambulatoriale 2, no. 2 (2024): 163–66. http://dx.doi.org/10.17473/1971-6818-2024-2-6.

Full text

Abstract:

Lo scompenso cardiaco rappresenta una tra le più frequenti tossicità cardiovascolari causate dai trattamenti oncologici, particolarmente rilevante in caso di trattamento con antracicline nel carcinoma mammario e nei linfomi e della terapia anti-HER2 nelle neoplasie mammarie. Oltre alle problematiche direttamente correlate allo scompenso per se, la sua insorgenza complica e spesso impedisce la prosecuzione di trattamenti fondamentali spesso con finalità curativa. Da ciò consegue che la sua precoce individuazione e l’impostazione di un trattamento specifico da parte del cardiologo/cardioncologo

APA, Harvard, Vancouver, ISO, and other styles

16

Федорец, Виктор Николаевич, София Фатхутдиновна Вершинина, Ирина Владиславовна Вологдина, et al. "Past, present and development possibility of cardiooncology." Medicine: theory and practice, no. 1 (May 16, 2022): 3–12. http://dx.doi.org/10.56871/6211.2022.35.75.001.

Full text

Abstract:

Материал посвящен новому междисциплинарному направлению «Кардиоонкология». Пациенты с онкологическими заболеваниями имеют повышенный риск развития сердечно -сосудистых осложнений, связанных с проводимой противоопухолевой терапией. В статье описаны исторические этапы применения противоопухолевого лечения, сопровождающегося возможным эффектом кардиотоксичности, представлено современное состояние проблемы и рассмотрены перспективы дальнейшего развития. Приведены данные российских и зарубежных исследований в этой области. The material is devoted to a new interdisciplinary direction “Cardioncology”

APA, Harvard, Vancouver, ISO, and other styles

17

Minotti, Giorgio. "The International Cardioncology Society–ONE trial: Not all that glitters is for cardioncologists only." European Journal of Cancer 97 (July 2018): 27–29. http://dx.doi.org/10.1016/j.ejca.2018.04.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

18

Quagliariello, Vincenzo, Annamaria Bonelli, Antonietta Caronna, et al. "SARS-CoV-2 Infection and Cardioncology: From Cardiometabolic Risk Factors to Outcomes in Cancer Patients." Cancers 12, no. 11 (2020): 3316. http://dx.doi.org/10.3390/cancers12113316.

Full text

Abstract:

The coronavirus disease-2019 (COVID-19) is a highly transmissible viral illness caused by SARS-CoV-2, which has been defined by the World Health Organization as a pandemic, considering its remarkable transmission speed worldwide. SARS-CoV-2 interacts with angiotensin-converting enzyme 2 and TMPRSS2, which is a serine protease both expressed in lungs, the gastro-intestinal tract, and cardiac myocytes. Patients with COVID-19 experienced adverse cardiac events (hypertension, venous thromboembolism, arrhythmia, myocardial injury, fulminant myocarditis), and patients with previous cardiovascular di

APA, Harvard, Vancouver, ISO, and other styles

19

Kogoniya, L. M., M. O. Rusanov, and V. E. Shikina. "Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors." Oncohematology 17, no. 3 (2022): 127–36. http://dx.doi.org/10.17650/1818-8346-2022-17-3-127-136.

Full text

Abstract:

Cardioncology has emerged as a new field at the intersection of cardiology and oncology. Despite the fact that improving efficiency of antitumor treatment increased the survival of oncological hematological patients, the long-term cardiovascular consequences of this treatment have become more clinically significant.Despite the effectiveness of modern methods of treatment, some drugs, such as Bcr-Abl kinase inhibitors, anthracyclines, HER2/Erbb2 inhibitors, vascular endothelial growth factor inhibitors, fluoropyrimidines, as well as radiation therapy can have a pronounced effect on the cardiova

APA, Harvard, Vancouver, ISO, and other styles

20

Lenihan, Daniel J., Daniela Cardinale, and Carlo M. Cipolla. "The Compelling Need for a Cardiology and Oncology Partnership and the Birth of the International CardiOncology Society." Progress in Cardiovascular Diseases 53, no. 2 (2010): 88–93. http://dx.doi.org/10.1016/j.pcad.2010.06.002.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Quagliariello, Vincenzo, Irma Bisceglia, Massimiliano Berretta, et al. "PCSK9 Inhibitors in Cancer Patients Treated with Immune-Checkpoint Inhibitors to Reduce Cardiovascular Events: New Frontiers in Cardioncology." Cancers 15, no. 5 (2023): 1397. http://dx.doi.org/10.3390/cancers15051397.

Full text

Abstract:

Cancer patients treated with immune checkpoint inhibitors (ICIs) are exposed to a high risk of atherosclerosis and cardiometabolic diseases due to systemic inflammatory conditions and immune-related atheroma destabilization. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key protein involved in metabolism of low-density lipoprotein (LDL) cholesterol. PCSK9 blocking agents are clinically available and involve monoclonal antibodies, and SiRNA reduces LDL levels in high-risk patients and atherosclerotic cardiovascular disease events in multiple patient cohorts. Moreover, PCSK9 induces

APA, Harvard, Vancouver, ISO, and other styles

22

Martos, Tamara, Laia Carla Belarte-Tornero, Mireia Ble, et al. "Abstract PO4-12-07: INSTITUTIONAL EXPERIENCE IN PATIENTS WITH EARLY BREAST CANCER WHO RECEIVED CARDIOTOXIC THERAPY IN CARDIONCOLOGY UNIT." Cancer Research 84, no. 9_Supplement (2024): PO4–12–07—PO4–12–07. http://dx.doi.org/10.1158/1538-7445.sabcs23-po4-12-07.

Full text

Abstract:

Abstract Introduction: Early breast cancer (eBC) is the most frequent malignancy diagnosed in women worldwide; fortunately, survival is increasing related to early diagnosis and the incorporation of new drugs. In this scenario, preventing long-term toxicities become essential. Cardiac adverse events related to anthracyclines or trastuzumab such as reduction in left ventricular (LV) systolic function and clinical heart failure (HF), are well known and are the leading cause of morbidity in breast cancer survivors. Cardioprotective strategies and early diagnoses of asymptomatic cardiac dysfunctio

APA, Harvard, Vancouver, ISO, and other styles

23

Lenihan, Daniel J., Gregory Hartlage, Jeanne DeCara, et al. "Cardio-Oncology Training: A Proposal From the International Cardioncology Society and Canadian Cardiac Oncology Network for a New Multidisciplinary Specialty." Journal of Cardiac Failure 22, no. 6 (2016): 465–71. http://dx.doi.org/10.1016/j.cardfail.2016.03.012.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Semeraro, Gennaro Carmine, Carlo Maria Cipolla, and Daniela Maria Cardinale. "Role of Cardiac Biomarkers in Cancer Patients." Cancers 13, no. 21 (2021): 5426. http://dx.doi.org/10.3390/cancers13215426.

Full text

Abstract:

In patients with cancer—and especially some specific subtypes—the heart can be pathologically affected due to the direct action of the tumor or its secretion products or due to the toxicity of some oncological treatments. Cardiac biomarkers have been investigated as inexpensive and easily accessible tools for prediction, early diagnosis, monitoring, or prognosis of various forms of cancer-related cardiac diseases. However, their clinical usefulness was not always clearly demonstrated in every area of cardioncology. For the identification of anthracycline related cardiotoxicity in the very earl

APA, Harvard, Vancouver, ISO, and other styles

25

Quagliariello, V., M. Iovine, I. Giacobbe, et al. "SOLUBLE GUANYLATE CYCLASE ACTIVATOR VERICIGUAT PREVENTS ANTHRACYCLINE–MEDIATED CARDIOTOXICITY AND SARCOPENIA THROUGH NO–SGC–CGMP–NLRP3 PATHWAY: POTENTIAL APPLICATION IN CANCER PATIENTS." European Heart Journal Supplements 26, Supplement_2 (2024): ii31. http://dx.doi.org/10.1093/eurheartjsupp/suae036.070.

Full text

Abstract:

Abstract Background Anthracycline–induced cardiomyopathies and sarcopenia are frequently seen in cancer patients, affecting their overall survival and quality of life; therefore, new cardioprotective strategies are needed in cardioncology. Vericiguat is a new oral guanylate cyclase activator that reduces heart failure hospitalizations or cardiovascular death through improvement of smooth muscle cell relaxation and reduction of myocardial fibrosis and inflammation. In this study, we highlight on the potential cardioprotective properties of vericiguat against anthracycline.mediated cardiotoxicit

APA, Harvard, Vancouver, ISO, and other styles

26

Эйнуллаева, Т. Р. "Ways to increase the effectiveness of hypertension correction during antitumor therapy with the use of VEGF inhibitors." Russian Journal of Physiotherapy, Balneology and Rehabilitation 22, no. 5 (2024): 319–28. http://dx.doi.org/10.17816/rjpbr628823.

Full text

Abstract:

In recent years, cardioncology has rapidly become responsible for comprehensive decision-making appropriate cancer patients receiving cardiotoxic cancer therapy. Currently, the implementation of a multidisciplinary approach in the correction of adverse events using various drug antitumor therapy regimens is becoming increasingly relevant. In particular, given the widespread use of vascular-endothelial growth factor inhibitors, both at the heart of complex schemes and in mono-supportive modes. It is important to timely identify and correct such a clinically significant adverse event as an incre

APA, Harvard, Vancouver, ISO, and other styles

27

Iovine, Martina, Vincenzo Quagliariello, Ilaria Giacobbe, et al. "Soluble guanylate cyclase activator vericiguat prevents anthracycline-mediated cardiotoxicity and sarcopenia through cGMP-NLRP3-cytokine pathway: Potential application in patients with cancer." Journal of Clinical Oncology 42, no. 16_suppl (2024): e24015-e24015. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.e24015.

Full text

Abstract:

e24015 Background: Anthracycline-induced cardiomyopathies and sarcopenia are frequently seen in cancer patients, affecting their overall survival and quality of life; therefore, new cardioprotective strategies are needed in cardioncology. Vericiguat is a new oral guanylate cyclase activator that reduces heart failure hospitalizations or cardiovascular death through improvement of smooth muscle cell relaxation and reduction of myocardial fibrosis and inflammation. In this study, we highlight on the potential cardioprotective properties of vericiguat against anthracycline.mediated cardiotoxicity

APA, Harvard, Vancouver, ISO, and other styles

28

Biondi, Filippo, and Rosalinda Madonna. "The Potential Role of GLP1-RAs Against Anticancer-Drug Cardiotoxicity: A Scoping Review." Journal of Clinical Medicine 14, no. 8 (2025): 2705. https://doi.org/10.3390/jcm14082705.

Full text

Abstract:

Background: GLP1 receptor agonists (GLP1-RAs) have become a central component in the treatment of type 2 diabetes mellitus (T2DM) and are gaining prominence in the cardiovascular field. Semaglutide and other GLP1-RA molecules possess cardioprotective properties. Cardiotoxicity, a term used to refer to cardiovascular disease caused by anticancer treatment, is a collection of common and severe conditions. Its pharmacological prevention or mitigation is a clinical unmet need as options are few and limited to some specific clinical settings. GLP1-RAs have a promising pharmacological profile given

APA, Harvard, Vancouver, ISO, and other styles

29

Maurea, Nicola, irma bisceglia, Andrea Paccone, Simona Buccolo, Martina Iovine та Vincenzo Quagliariello. "DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT-TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL-1β: A FIRST EVIDENCE OF SGLT-2/PCSK9 CROSS-TALK IN CARDIONCOLOGY". Journal of the American College of Cardiology 81, № 8 (2023): 2269. http://dx.doi.org/10.1016/s0735-1097(23)02713-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Quagliariello, Vincenzo, Manuela Giovanna Basilicata, Giacomo Pepe, et al. "Combination of Spirulina platensis, Ganoderma lucidum and Moringa oleifera Improves Cardiac Functions and Reduces Pro-Inflammatory Biomarkers in Preclinical Models of Short-Term Doxorubicin-Mediated Cardiotoxicity: New Frontiers in Cardioncology?" Journal of Cardiovascular Development and Disease 9, no. 12 (2022): 423. http://dx.doi.org/10.3390/jcdd9120423.

Full text

Abstract:

Anthracyclines are essential adjuvant therapies for a variety of cancers, particularly breast, gastric and esophageal cancers. Whilst prolonging cancer-related survival, these agents can induce drug-related cardiotoxicity. Spirulina, Reishi (Ganoderma lucidum) and Moringa are three nutraceuticals with anti-inflammatory effects that are currently used in cancer patients as complementary and alternative medicines to improve quality of life and fatigue. We hypothesize that the nutraceutical combination of Spirulina, Reishi and Moringa (Singo) could reduce inflammation and cardiotoxicity induced b

APA, Harvard, Vancouver, ISO, and other styles

31

Quagliariello, V., G. Palma, A. Luciano та ін. "P383 DAPAGLIFLOZIN REDUCES SYSTEMIC PCSK9 LEVELS IN PRECLINICAL MODELS OF SHORT–TERM DOXORUBICIN CARDIOTOXICITY THROUGH NLRP3 INFLAMMASOME/IL–1Β: A FIRST EVIDENCE OF SGLT–2/PCSK9 CROSS–TALK IN CARDIONCOLOGY". European Heart Journal Supplements 25, Supplement_D (2023): D195. http://dx.doi.org/10.1093/eurheartjsupp/suad111.455.

Full text

Abstract:

Abstract Background Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. In recent five years, it was demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9), a lipid metabolism–related protein, is a key orchestrator of immune infiltration in myocardial and cancer tissues and could regulate cardiac fibrosis and inflammatio

APA, Harvard, Vancouver, ISO, and other styles

32

Fioretti, A., T. Leopizzi, P. Pizzutilo, et al. "P393 EDOXABAN: NEW PERSPECTIVE IN A PATIENT WITH CANCER–ASSOCIATED THROMBOSIS COMPLICATED BY BRAIN METASTASES. A RARE CLINICAL CASE." European Heart Journal Supplements 25, Supplement_D (2023): D198—D199. http://dx.doi.org/10.1093/eurheartjsupp/suad111.464.

Full text

Abstract:

Abstract Herein, we present the case of a 58 y–o Caucasian man with unremarkable cardiovascular history and a strong family history for cancer. He was diagnosed with lung adenocarcinoma IVb (pleura, pleural effusion, lymph nodes), PDL1: 2% TPS and absence of actionable driver mutations on DNA and RNA NGS (only ERBB2 mutation). Started first–line chemotherapy with cisplatin–pemetrexed regimen and immunotherapy with pembrolizumab. He developed common/superficial femoral and popliteal deep vein thrombosis (DVT) and pulmonary embolism (PE). The patient started low–molecular–weight heparin (LMWH) n

APA, Harvard, Vancouver, ISO, and other styles

33

Valenti, C., G. Moretti, S. Copelli, et al. "P280 TEAMWORK IS SUCCESSFUL (1): FAVOUREABLE RE–CHALLENGE OF DOUBLE ANTI–HER2 TREATMENT IN SEVERE MYOCARDIAL DYSFUNCTION IN PATIENT WITH ADVANCED BREAST CANCER AND OCCULT TYPE II DIABETES." European Heart Journal Supplements 25, Supplement_D (2023): D149—D150. http://dx.doi.org/10.1093/eurheartjsupp/suad111.354.

Full text

Abstract:

Abstract Introduction Cardiovascular diseases (CVD) and Cancer (C), the most important causes of mortality worldwide. share many risk factors and common pathophysiological processes such as chronic inflammation and unfavorable cardio–metabolic profile. Progress in oncological treatments improved the survival of oncological patients (Pt) but have increased the likelihood of short– and long–term CV cardiovascular complications. The multidisciplinary collaboration between cardiologist and onco–hematologists is the task of Cardioncology, an emerging new sub–specialization of clinical cardiology th

APA, Harvard, Vancouver, ISO, and other styles

34

Iovine, Martina, Vincenzo Quagliariello, Margherita Passariello, et al. "Effect of anti CTLA-4 and PD-1 monoclonal antibodies on systemic SDF-1 and galectin-3 levels through NLRP3 and MyD-88 pathways in preclinical models." Journal of Clinical Oncology 42, no. 16_suppl (2024): 12032. http://dx.doi.org/10.1200/jco.2024.42.16_suppl.12032.

Full text

Abstract:

12032 Background: Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed. Methods: Firstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72h. After treatment, production of DAMPs and

APA, Harvard, Vancouver, ISO, and other styles

35

Madeira Timóteo Dias, Isabela Carolina, Eloá Carneiro Carvalho, Ana Lúcia Cascardo Marins, Andrezza Serpa Franco, Norma Valéria Dantas de Oliveira Souza, and Karla Biancha Silva de Andrade. "Avaliação de risco para tromboembolismo venoso: estudo bibliométrico para a prática clínica de cardioncologia." Revista Enfermagem Atual In Derme 96, no. 39 (2022). http://dx.doi.org/10.31011/reaid-2022-v.96-n.39-art.1438.

Full text

Abstract:

Objetivo: identificar as produções científicas acerca das estratégias de avaliação de risco para tromboembolismo venoso, para aplicação pelo enfermeiro no cuidado ao paciente oncológico. Métodos: trata-se de uma pesquisa de revisão, tipo bibliométrica, de natureza descritiva e abordagem quantitativa. Resultados: foram encontradas 133 publicações e selecionados 34 textos após análise conforme os critérios de inclusão. Dos 34 artigos que participaram da pesquisa, 23 (67,6%) trabalharam com aplicação de escalas de avaliação de risco para tromboembolismo venoso, onde 14 (41,2%) abordavam o escore

APA, Harvard, Vancouver, ISO, and other styles

36

"Cardioncology and Cardiotoxicity." European Heart Journal Supplements 21, Supplement_J (2019): J39—J44. http://dx.doi.org/10.1093/eurheartj/suz248.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

Cardinale, Daniela, Michela Salvatici, and Maria T. Sandri. "Role of biomarkers in cardioncology." Clinical Chemistry and Laboratory Medicine (CCLM) 49, no. 12 (2011). http://dx.doi.org/10.1515/cclm.2011.692.

Full text

Abstract:

AbstractCardiotoxicity is a serious adverse effect of anticancer drugs, impacting on quality of life and overall survival of cancer patients. According to the current standard for monitoring cardiac function, cardiotoxicity is usually detected only when a functional impairment has already occurred, precluding any chance of preventing its development. Over the last decade, however, a new approach, based on the use of cardiac biomarkers, has emerged, and has proven to be an effective alternative strategy for early detection of subclinical cardiac injury. In particular, the role of troponin I in

APA, Harvard, Vancouver, ISO, and other styles

38

Chazova, I. E., E. V. Oschepkova, M. Yu Kirillova, and G. Ch Sharipova. "Cardioncology: management of arterial hypertension in patients with cancer on chemotherapy." Systemic Hypertension 12, no. 2 (2015). http://dx.doi.org/10.26442/2075-082x_12.2.6-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Tlegenova, Zhenisgul, and Saule Balmagambetova. "Comments on new 2022 European Society of Cardiology guidelines on cardioncology." Heart, Vessels and Transplantation, Ahead of Print (January 21, 2023). http://dx.doi.org/10.24969/hvt.2023.370.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Magnesa, Michele, Grazia Casavecchia, Roberta Barone, Mariolina Riccardo, Delia Corbo, and Natale Daniele Brunetti. "682 Cardioncology: is it time to spread the need for dedicated management?" European Heart Journal Supplements 23, Supplement_G (2021). http://dx.doi.org/10.1093/eurheartj/suab130.001.

Full text

Abstract:

Abstract Case report A 56-year-old man affected by micromolecular multiple myeloma was treated by several cycles of different chemotherapy drugs from September 2015 to December 2020. The chemotherapy regimen included 4-cycle first-line therapy with Bortezomib, Thalidomide, and Dexamethasone; 19-cycle second-line therapy with Carfilzomib, Revlimid, and Dexamethasone; 8-cycle third-line therapy with Daratumumab, Revlimid, and Dexamethasone; finally, he was started on therapy with Pomalidomide and Endoxan. During the various treatments, the patient did not follow a dedicated cardiological follow-

APA, Harvard, Vancouver, ISO, and other styles

41

Cardinale, Daniela, Gina Biasillo, and Carlo Maria Cipolla. "Curing Cancer, Saving the Heart: A Challenge That Cardioncology Should Not Miss." Current Cardiology Reports 18, no. 6 (2016). http://dx.doi.org/10.1007/s11886-016-0731-z.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Fabiani, Iacopo, Carlo Maria Cipolla, Nicola Colombo, and Daniela Cardinale. "Cardioncological Approach for Trastuzumab Therapy in Breast Cancer Patients With Cardiotoxicity: Impact on Adherence and Clinical Outcome." Frontiers in Pharmacology 11 (August 4, 2020). http://dx.doi.org/10.3389/fphar.2020.01190.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Chianca, Michela, Iacopo Fabiani, Annamaria Del Franco, et al. "Management and treatment of cardiotoxicity due to anticancer drugs: 10 questions and answers." European Journal of Preventive Cardiology, August 8, 2022. http://dx.doi.org/10.1093/eurjpc/zwac170.

Full text

Abstract:

Abstract Since the introduction of anthracyclines into clinical practice in the 1960s, chemotherapy have always been associated to cardiotoxicity. Patients on cardiotoxic drugs can develop a wide range of cardiovascular diseases, including left ventricular (LV) systolic dysfunction and heart failure (HF), arrhythmias, hypertension, and coronary artery disease (CAD). The rising number of cancer patients, population aging, and the frequent overlap of cardiovascular and oncological diseases have highlighted the importance of close collaboration between cardiologists and oncologists. As a result,

APA, Harvard, Vancouver, ISO, and other styles

44

Di Lisi, Daniela, Cristina Madaudo, Alfredo Ruggero Galassi, and Giuseppina Novo. "Higher Incidence of Chemotherapy-Related Cardiac Dysfunction after Third Wave COVID-19 Pandemic: A Single Cardioncology Centre Experience." SSRN Electronic Journal, 2022. http://dx.doi.org/10.2139/ssrn.4055863.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Quagliariello, V., I. Bisceglia, M. Canale, et al. "COMBINATION THERAPY WITH SEMAGLUTIDE AND VERICIGUAT AS AN EFFECTIVE THERAPY OF OF 5–FU INDUCED CARDIOTOXICITY: PRELIMINARY EVIDENCES IN CARDIONCOLOGY." European Heart Journal Supplements 27, Supplement_5 (2025). https://doi.org/10.1093/eurheartjsupp/suaf076.253.

Full text

Abstract:

Abstract Background Patients treated with 5–FU are exposed to high risk of acute chest pain, myocardial infarction, heart failure, arrhythmias, and sudden cardiac death. These patients need new cardioprotective strategies to reduce cardiovascular mortality. Vericiguat is a soluble guanylate cyclase (sGC) stimulator. It is used for the treatment of heart failure characterized by reduced ejection fraction. GLP–1 receptor agonists, like semaglutide, have shown cardiorenal benefits in patients with/without diabetes, proposing themselves as a new cardioprotective strategy in a broad patient setting

APA, Harvard, Vancouver, ISO, and other styles

46

Maurea, Nicola, Maria Laura Canale, Irma Bisceglia, et al. "Abstract 15043: Dapagliflozin Reduces Systemic NLRP-3, IL-1 and PCSK9 Levels in Preclinical Models of Short-Term Doxorubicin Cardiotoxicity: New Evidences of SGLT2i Use in Cardioncology." Circulation 148, Suppl_1 (2023). http://dx.doi.org/10.1161/circ.148.suppl_1.15043.

Full text

Abstract:

Background: Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. In recent five years, it was demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9), a lipid metabolism-related protein, is a key orchestrator of immune infiltration in myocardial and cancer tissues and could regulate cardiac fibrosis and inflammation. PCSK9

APA, Harvard, Vancouver, ISO, and other styles

47

Maurea, N., M. L. Canale, M. Scherillo, et al. "SGLT2i Dapagliflozin decreases NLRP3, IL-1 and PCSK9 expression in preclinical models of short-term doxorubicin cardiotoxicity." European Heart Journal 44, Supplement_2 (2023). http://dx.doi.org/10.1093/eurheartj/ehad655.2683.

Full text

Abstract:

Abstract Background Anthracyclines are an effective and widely used chemotherapy agent in the treatment of multiple solid organ tumors and hematologic malignancies. The use of anthracyclines as a standard cancer therapy is limited by the potential for the development of cardiac dysfunction, arrhythmias, and clinical heart failure. In recent five years, it was demonstrated that proprotein convertase subtilisin/kexin type 9 (PCSK9), a lipid metabolism-related protein, is a key orchestrator of immune infiltration in myocardial and cancer tissues and could regulate cardiac fibrosis and inflammatio

APA, Harvard, Vancouver, ISO, and other styles

48

Quagliariello, Vincenzo, Margherita Passariello, Annabella Di Mauro, et al. "Immune checkpoint inhibitor therapy increases systemic SDF-1, cardiac DAMPs Fibronectin-EDA, S100/Calgranulin, galectine-3, and NLRP3-MyD88-chemokine pathways." Frontiers in Cardiovascular Medicine 9 (September 8, 2022). http://dx.doi.org/10.3389/fcvm.2022.930797.

Full text

Abstract:

BackgroundImmune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed.MethodsFirstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72 h. After treatment, production of DAMPs and 12 cytokin

APA, Harvard, Vancouver, ISO, and other styles

49

Quagliariello, Vincenzo, Margherita Passariello, Annabella Di Mauro, et al. "201 CTLA-4 AND PD-1 BLOCKING AGENTS INCREASES SYSTEMIC SDF-1, CARDIAC DAMPS FIBRONECTIN EDA, S-100 CALGRANULIN, GALECTINE-3 AND NLRP-3/MYD-88 CHEMOKINE PATHWAYS." European Heart Journal Supplements 24, Supplement_K (2022). http://dx.doi.org/10.1093/eurheartjsupp/suac121.133.

Full text

Abstract:

Abstract Background Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases.In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed. Methods Firstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72h. After treatment, production of DAMPs and

APA, Harvard, Vancouver, ISO, and other styles

50

Maurea, N., C. De Lorenzo, M. Passariello, et al. "Anti CTLA-4 and PD-1 monoclonal antibodies increases systemic SDF-1 and galectin-3 levels and reduces myocardial strain through NLRP3 and MyD-88 pathways." European Heart Journal 44, Supplement_2 (2023). http://dx.doi.org/10.1093/eurheartj/ehad655.2684.

Full text

Abstract:

Abstract Background Immune checkpoint inhibitors (ICIs) have significantly changed the oncology clinic in recent years, improving survival expectations in cancer patients. ICI therapy have a broad spectrum of side effects from endocrinopathies to cardiovascular diseases. Purpose In this study, pro-inflammatory and pro-fibrotic effects of short-term ICIs therapy in preclinical models were analyzed. Methods Firstly, in a human in vitro model, human cardiomyocytes co-cultured with hPBMC were exposed to ICIs (with CTLA-4 or PD-1 blocking agents, at 200 nM) for 72h. After treatment, production of D

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!